FindTrial
Sign In

Dose-effect relationship and safety of intravenous infusion of different doses of oxytocin in patients with adenomyosis

Dose-effect relationship and safety of intravenous infusion of different doses of oxytocin in patients with adenomyosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017048
Enrollment
Unknown
Registered
2018-07-10
Start date
2018-07-10
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyosis

Interventions

Group A:intravenous drop oxytocin with 0.06U/min
Group B:intravenous drop oxytocin with 0.12U/min
Group C:intravenous drop oxytocin with 0.24U/min
Group D:intravenous drop oxytocin with 0.36U/min

Sponsors

HIFU Center for Tumor Therapy, First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 55 Years

Inclusion criteria

Inclusion criteria: The uterine adenomyosis diagnosed by MRI,the thickness of uterine wall is greater than 30mm;Patients who agree to the oxytocin sensitivity test

Exclusion criteria

Exclusion criteria: Serious organic diseases of important organs were combined: diabetes, malignant hypertension, history of myocardial infarction, heart failure, liver and kidney failure, etc.Patients with a history of OT allergy or allergies to more than 3 drugs.

Design outcomes

Primary

MeasureTime frame
Ultrasonic measurement of internal and peripheral blood flow parameters of the lesion;adverse drug reaction;—

Countries

China

Contacts

Public ContactJinyun Chen

College of Biomedical Engineering, Chongqing Medical University

chenjinyun2006@126.com+86 13668029697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026